

Christopher R Cogle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/201960/publications.pdf>

Version: 2024-02-01

215
papers

6,282
citations

94269

37
h-index

76769

74
g-index

216
all docs

216
docs citations

216
times ranked

8750
citing authors

#	ARTICLE	IF	CITATIONS
1	DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks. <i>Clinical Cancer Research</i> , 2022, 28, 756-769.	3.2	9
2	Specialized Proresolving Mediators in Symptomatic Women With Coronary Microvascular Dysfunction (from the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD [WARRIOR]) Tj ETQq0 0 0ogBT /Overclock 10 Tf		
3	Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation. <i>Journal of Clinical Oncology</i> , 2022, 40, 772-783.	0.8	7
4	Impact of the COVID-19 Pandemic on Colorectal and Prostate Cancer Screening in a Large U.S. Health System. <i>Healthcare (Switzerland)</i> , 2022, 10, 264.	1.0	13
5	HOTTIP-dependent R-loop formation regulates CTCF boundary activity and TAD integrity in leukemia. <i>Molecular Cell</i> , 2022, 82, 833-851.e11.	4.5	48
6	Finding incident cancer cases through outpatient oncology clinic claims data and integration into a state cancer registry. <i>Cancer Causes and Control</i> , 2021, 32, 199-202.	0.8	0
7	Building a precision oncology workforce by multidisciplinary and case-based learning. <i>BMC Medical Education</i> , 2021, 21, 75.	1.0	7
8	Vaccine Enthusiasm and Hesitancy in Cancer Patients and the Impact of a Webinar. <i>Healthcare (Switzerland)</i> , 2021, 9, 351.	1.0	62
9	Implementation of Cancer Plans in the United States: A Review. <i>Healthcare (Switzerland)</i> , 2021, 9, 291.	1.0	0
10	Following the Breadcrumbs of Palliative Care Financial Sustainability to Big Data. <i>Journal of Palliative Medicine</i> , 2021, 24, 649-650.	0.6	0
11	A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. <i>Cancers</i> , 2021, 13, 4113.	1.7	20
12	Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms. <i>Future Oncology</i> , 2021, 17, 263-277.	1.1	5
13	Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436. <i>Cancers</i> , 2021, 13, 5287.	1.7	4
14	Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial. <i>Blood</i> , 2021, 138, 1277-1277.	0.6	0
15	Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial. <i>Blood</i> , 2021, 138, 875-875.	0.6	0
16	Risk and Severity of Cytokine Release Syndrome in Patients with Relapsed/Refractory (R/R) AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436. <i>Blood</i> , 2021, 138, 3416-3416.	0.6	0
17	Direct Intravital Imaging of the Bone Marrow and Splenic Hematopoietic Niches in Individual Mice to Define the Early Engraftment Kinetics Following HSC-Transplant. <i>Blood</i> , 2021, 138, 3812-3812.	0.6	0
18	Tolerability and Single Agent Anti-Neoplastic Activity of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory AML or MDS. <i>Blood</i> , 2021, 138, 3415-3415.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial. <i>Blood</i> , 2021, 138, 1279-1279.	0.6	0
20	Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA. <i>Frontiers in Oncology</i> , 2021, 11, 806243.	1.3	1
21	Clinical predictors of delayed engraftment in autologous hematopoietic cell transplant recipients. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 23-31.	0.6	9
22	A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Cancers</i> , 2020, 12, 74.	1.7	21
23	Transplant Referral Patterns for Patients (Pts) with Newly Diagnosed (ND) Higher-Risk (HR) Myelodysplastic Syndromes (MDS), and European Leukemianet (ELN) 2010 Intermediate-Risk (IR) or Adverse-Risk (AR) Acute Myeloid Leukemia (AML) in the ConnectA® MDS/AML Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S98-S99.	2.0	2
24	Patient and physician perceptions about blood transfusions in the myelodysplastic syndromes. <i>Leukemia Research</i> , 2020, 96, 106425.	0.4	1
25	Cancer in the Time of Coronavirus: A Call for Crisis Oncology Standards of Care. <i>Healthcare (Switzerland)</i> , 2020, 8, 214.	1.0	2
26	Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the ConnectA®MDS/AML Disease Registry. <i>EJHaem</i> , 2020, 1, 58-68.	0.4	5
27	Functional Dependency Analysis Identifies Potential Druggable Targets in Acute Myeloid Leukemia. <i>Cancers</i> , 2020, 12, 3710.	1.7	6
28	Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3323.	1.8	3
29	Clinical Application of Computational Methods in Precision Oncology. <i>JAMA Oncology</i> , 2020, 6, 1282.	3.4	15
30	Identification of Unique mRNA and miRNA Expression Patterns in Bone Marrow Hematopoietic Stem and Progenitor Cells After Trauma in Older Adults. <i>Frontiers in Immunology</i> , 2020, 11, 1289.	2.2	7
31	Absolute Lymphocyte Count Recovery Following Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S301-S302.	2.0	0
32	Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2020, 189, e211-e213.	1.2	9
33	Interleukin-8 blockade prevents activated endothelial cell mediated proliferation and chemoresistance of acute myeloid leukemia. <i>Leukemia Research</i> , 2019, 84, 106180.	0.4	41
34	Diagnostic Testing Patterns for Ring Sideroblasts (RS) in Patients with Newly Diagnosed Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the ConnectA® MDS/AML Disease Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S343-S344.	0.2	0
35	Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging Expertise. <i>Journal of Clinical Oncology</i> , 2019, 37, 1690-1694.	0.8	12
36	Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis. <i>Leukemia Research</i> , 2019, 81, 43-49.	0.4	4

#	ARTICLE	IF	CITATIONS
37	Continuous Rural-Urban Coding for Cancer Disparity Studies: Is It Appropriate for Statistical Analysis?. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 1076.	1.2	16
38	Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 251-254.	0.2	5
39	A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients. <i>Blood Advances</i> , 2019, 3, 1837-1847.	2.5	10
40	HOTTIP lncRNA Promotes Hematopoietic Stem Cell Self-Renewal Leading to AML-like Disease in Mice. <i>Cancer Cell</i> , 2019, 36, 645-659.e8.	7.7	116
41	Predicting response to BET inhibitors using computational modeling: A BEAT AML project study. <i>Leukemia Research</i> , 2019, 77, 42-50.	0.4	16
42	Computational modeling of early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) to identify personalized therapy using genomics. <i>Leukemia Research</i> , 2019, 78, 3-11.	0.4	11
43	Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect [®] MDS/AML Registry. <i>Blood</i> , 2019, 134, 4747-4747.	0.6	0
44	Differing Perceptions between Myelodysplastic Syndrome (MDS) Patients and Providers Regarding Blood Transfusions. <i>Blood</i> , 2019, 134, 5418-5418.	0.6	0
45	Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation. <i>Journal of Clinical Apheresis</i> , 2018, 33, 29-37.	0.7	36
46	Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study. <i>Leukemia Research</i> , 2018, 64, 34-41.	0.4	41
47	CD34+ chimerism analysis for minimal residual disease monitoring after allogeneic hematopoietic cell transplantation. <i>Leukemia Research</i> , 2018, 74, 110-112.	0.4	6
48	Functional genomic landscape of acute myeloid leukaemia. <i>Nature</i> , 2018, 562, 526-531.	13.7	907
49	Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation. <i>Clinical Cancer Research</i> , 2018, 24, 4098-4109.	3.2	9
50	CTCF boundary remodels chromatin domain and drives aberrant HOX gene transcription in acute myeloid leukemia. <i>Blood</i> , 2018, 132, 837-848.	0.6	56
51	Exploring the Structure-Activity Relationship and Mechanism of a Chromene Scaffold (CXL Series) for Its Selective Antiproliferative Activity toward Multidrug-Resistant Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 6892-6903.	2.9	11
52	CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia. <i>Leukemia Research</i> , 2018, 72, 79-85.	0.4	20
53	Factors Associated with Early Therapy Initiation in Patients (pts) with Myelodysplastic Syndromes (MDS) in the Connect [®] MDS/AML Disease Registry. <i>Blood</i> , 2018, 132, 4731-4731.	0.6	1
54	Mechanisms of Azacitidine Chemotherapy Resistance in AML and MDS and New Therapy Options. <i>Blood</i> , 2018, 132, 5506-5506.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Predicting Response to BET Inhibitor in Combination with Palbociclib / Sorafenib Using a Computational Model and Its Validation: A Beat AML Project Study. <i>Blood</i> , 2018, 132, 1540-1540.	0.6	1
56	WT1 and BCORL1 Identified By Computational Biology Modeling Analysis of Patient Genomics Are Novel Predictors of Response to Azacitidine (AZA) and Lenalidomide (LEN) Treatment in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 1538-1538.	0.6	0
57	Healthcare Resource Utilization (HCRU) in Patients (pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated in the Connect [®] MDS/AML Disease Registry. <i>Blood</i> , 2018, 132, 4736-4736.	0.6	0
58	AraC-Daunorubicin-Etoposide (ADE) Response Prediction in Pediatric AML Patients Using a Computational Biology Modeling (CBM) Based Precision Medicine Workflow. <i>Blood</i> , 2018, 132, 4034-4034.	0.6	0
59	Predicting Response to Dasatinib Using a Computational Model and Its Validation: A Beat AML Project Study. <i>Blood</i> , 2018, 132, 1541-1541.	0.6	0
60	Predictive Analysis on Prognostic Impact of Monosomy 7 in AML and Identified Therapy Options for This Cohort. <i>Blood</i> , 2018, 132, 1539-1539.	0.6	1
61	Analysis of the Evolving MDS/AML Clones to Identify Resistance Mechanisms and Predict New Therapy Options at Relapse Using Computational Biology Modeling: Case-Studies from iCare1 Clinical Study. <i>Blood</i> , 2018, 132, 3086-3086.	0.6	0
62	Azacitidine Response Prediction in MDS Patients with NGS Data Using a Computational Biology Modeling (CBM) Based Clinical Decision Support System. <i>Blood</i> , 2018, 132, 3087-3087.	0.6	0
63	Predicting Carfilzomib Resistance Mechanisms and Therapeutics Using Computational Modelling of Genomics and Proteomics. <i>Blood</i> , 2018, 132, 3193-3193.	0.6	0
64	Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor. <i>Molecular Therapy - Oncolytics</i> , 2017, 4, 31-40.	2.0	27
65	Peripheral Blood Cytokine Levels After Acute Myocardial Infarction. <i>Circulation Research</i> , 2017, 120, 1947-1957.	2.0	33
66	The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail. <i>Oncologist</i> , 2017, 22, 379-385.	1.9	16
67	Refractory macrocytic anemias in patients with clonal hematopoietic disorders and isolated mutations of the spliceosome gene ZRSR2. <i>Leukemia Research</i> , 2017, 61, 104-107.	0.4	7
68	Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 478-483.	1.2	7
69	Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence. <i>Leukemia Research</i> , 2017, 60, 123-128.	0.4	8
70	Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2017, 7, 634.	2.8	21
71	Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients. <i>Leukemia Research</i> , 2017, 52, 1-7.	0.4	14
72	Association of breast carcinoma growth with a non-canonical axis of IFN ³ /IDO1/TSP1. <i>Oncotarget</i> , 2017, 8, 85024-85039.	0.8	14

#	ARTICLE	IF	CITATIONS
73	Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies. <i>Viruses</i> , 2016, 8, 85.	1.5	8
74	Effect of melphalan 140Âmg/m ² vs 200Âmg/m ² on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantationâ€”a single center experience. <i>Clinical Transplantation</i> , 2016, 30, 894-900.	0.8	14
75	An injectable capillary-like microstructured alginate hydrogel improves left ventricular function after myocardial infarction in rats. <i>International Journal of Cardiology</i> , 2016, 220, 149-154.	0.8	31
76	Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial. <i>American Heart Journal</i> , 2016, 179, 142-150.	1.2	18
77	Identification of Bone Marrow Cell Subpopulations Associated with Improved Functional Outcomes in Patients with Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial. <i>Cell Transplantation</i> , 2016, 25, 1675-1687.	1.2	32
78	A new model to predict remission status in AML patients based on day 14 bone marrow biopsy. <i>Leukemia Research</i> , 2016, 46, 69-73.	0.4	12
79	Circulating progenitor cells and coronary microvascular dysfunction: Results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation â€” Coronary Vascular Dysfunction Study (WISE-CVD). <i>Atherosclerosis</i> , 2016, 253, 111-117.	0.4	11
80	Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. <i>BMC Cancer</i> , 2016, 16, 652.	1.1	12
81	Angiotensin II Regulation of Proliferation, Differentiation, and Engraftment of Hematopoietic Stem Cells. <i>Hypertension</i> , 2016, 67, 574-584.	1.3	50
82	Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells. <i>Cytotherapy</i> , 2016, 18, 465-480.	0.3	21
83	Chemosensitizing AML cells by targeting bone marrow endothelial cells. <i>Experimental Hematology</i> , 2016, 44, 363-377.e5.	0.2	22
84	Costâ€”effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 275-284.	0.7	4
85	Clinical significance of <i>in vivo</i> cytarabine-induced gene expression signature in AML. <i>Leukemia and Lymphoma</i> , 2016, 57, 909-920.	0.6	7
86	Acute myeloid leukemia in the vascular niche. <i>Cancer Letters</i> , 2016, 380, 552-560.	3.2	53
87	A Genomic Signature Predicting Venetoclax Treatment Response in AML Identified By Protein Network Mapping and Validated By Ex Vivo Drug Sensitivity Testing: A Beat AML Project Study. <i>Blood</i> , 2016, 128, 1713-1713.	0.6	1
88	A Genomic Rule Predicting HMA Treatment Response in MDS Identified By Protein Network Mapping and Validated By Clinical Trial Simulation. <i>Blood</i> , 2016, 128, 3151-3151.	0.6	2
89	Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECTÂ® Myelodysplastic Syndromes (MDS) and AML Disease Registry. <i>Blood</i> , 2016, 128, 3548-3548.	0.6	4
90	A Phase 1b (OX1222) Dose-Finding Study of OXi4503 Combined with Cytarabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. <i>Blood</i> , 2016, 128, 4037-4037.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Ex Vivo High-Throughput Flow Cytometry Screening Identifies Subsets of Responders to Differentiation Agents in Individual AML Patient Samples. <i>Blood</i> , 2016, 128, 5206-5206.	0.6	4
92	Icare 1: A Prospective Clinical Trial to Predict Treatment Response Based on Mutanome-Informed Computational Biology in Patients with AML and MDS. <i>Blood</i> , 2016, 128, 594-594.	0.6	5
93	CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies. <i>Blood</i> , 2016, 128, 905-905.	0.6	8
94	Use of Genomic Information to Predict Treatment Response in Multiple Myeloma Patients By Computational Mapping of Protein Network Disturbances. <i>Blood</i> , 2016, 128, 2099-2099.	0.6	0
95	Impact of Novel Agents on Frequency of Second Salvage Autologous Transplantation in Patients with Multiple Myeloma. <i>Blood</i> , 2016, 128, 5832-5832.	0.6	0
96	Early Treatment Initiation in Myelodysplastic Syndromes (MDS) Produces Higher Rate of and Earlier Transfusion Independence. <i>Blood</i> , 2016, 128, 395-395.	0.6	5
97	Vitamin D effect on umbilical cord blood characteristics: a comparison between African Americans and Caucasians. <i>Transfusion</i> , 2015, 55, 1766-1771.	0.8	5
98	Prevention of EBV lymphoma development by oncolytic myxoma virus in a murine xenograft model of post-transplant lymphoproliferative disease. <i>Biochemical and Biophysical Research Communications</i> , 2015, 462, 283-287.	1.0	6
99	Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells. <i>Blood</i> , 2015, 125, 3778-3788.	0.6	29
100	Two novel RUNX1 mutations in a patient with congenital thrombocytopenia that evolved into a high grade myelodysplastic syndrome. <i>Leukemia Research Reports</i> , 2015, 4, 24-27.	0.2	17
101	Bone Marrow Characteristics Associated With Changes in Infarct Size After STEMI. <i>Circulation Research</i> , 2015, 116, 99-107.	2.0	65
102	Bone marrow niche in the myelodysplastic syndromes. <i>Leukemia Research</i> , 2015, 39, 1020-1027.	0.4	61
103	Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>Oncologist</i> , 2015, 20, 1404-1412.	1.9	32
104	Incidence and Burden of the Myelodysplastic Syndromes. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 272-281.	1.2	108
105	Endothelial cell derived angiocrine support of acute myeloid leukemia targeted by receptor tyrosine kinase inhibition. <i>Leukemia Research</i> , 2015, 39, 984-989.	0.4	20
106	A Patient-Specific Ex Vivo Screening Platform for Personalized Acute Myeloid Leukemia (AML) Therapy. <i>Blood</i> , 2015, 126, 1352-1352.	0.6	5
107	Gene Mutations in MDS Associating with Peripheral Blood Count Abnormalities. <i>Blood</i> , 2015, 126, 1685-1685.	0.6	1
108	The Vascular Disrupting Agent OXi4503 in Relapsed and Refractory AML and MDS. <i>Blood</i> , 2015, 126, 4936-4936.	0.6	4

#	ARTICLE	IF	CITATIONS
109	Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies. <i>PLoS ONE</i> , 2015, 10, e0135520.	1.1	54
110	Angiotensin II-induced Hypertension Impairs Hematopoietic Stem Cell Homing and Engraftment. <i>FASEB Journal</i> , 2015, 29, 670.5.	0.2	0
111	Effect of Melphalan 140 Mg/m ² Versus 200 Mg/m ² on Toxicities and Outcomes in Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 1988-1988.	0.6	0
112	A New Model to Predict Remission Status in Acute Myeloid Leukemia (AML) Patients Based on Day 14 Bone Marrow (D14 BM) Biopsy. <i>Blood</i> , 2015, 126, 3852-3852.	0.6	0
113	Predicting MDS Response to Drug Therapies Based on a New Method of Interpreting the MDS Mutanome. <i>Blood</i> , 2015, 126, 96-96.	0.6	0
114	Minimal Residual Disease (MRD) By Either Flow Cytometry or Cytogenetics Prior to an Allogeneic Hematopoietic Cell Transplant (allo-HCT) Predicts Poor Acute Myeloid Leukemia (AML) Outcomes. <i>Blood</i> , 2015, 126, 3221-3221.	0.6	0
115	Tandem Autologous Stem Cell Transplantation for Multiple Myeloma Patients Based on Response to Their First Transplant—A Prospective Phase II Study. <i>Clinical Medicine Insights: Oncology</i> , 2014, 8, CMO.S16835.	0.6	5
116	Fishing for myelodysplastic syndromes finds uncaptured cases by state cancer registries: Need for more resources. <i>Cancer</i> , 2014, 120, 1614-1616.	2.0	1
117	Radiation Alone for Solid Tumors and the Questionable Development of Therapy-Related Myelodysplastic Syndromes. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju025-dju025.	3.0	2
118	Response to Letter Regarding Article, “A Detailed Analysis of Bone Marrow From Patients with Ischemic Heart Disease and Left Ventricular Dysfunction: BM CD34, CD11b and Clonogenic Capacity as Biomarkers for Clinical Outcomes” <i>Circulation Research</i> , 2014, 115, e36-7.	2.0	1
119	Detailed Analysis of Bone Marrow From Patients With Ischemic Heart Disease and Left Ventricular Dysfunction. <i>Circulation Research</i> , 2014, 115, 867-874.	2.0	65
120	Functional integration of acute myeloid leukemia into the vascular niche. <i>Leukemia</i> , 2014, 28, 1978-1987.	3.3	75
121	High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment. <i>Leukemia Research</i> , 2014, 38, 71-75.	0.4	30
122	Mapping hematopoiesis in a fully regenerative vertebrate: the axolotl. <i>Blood</i> , 2014, 124, 1232-1241.	0.6	59
123	Treatment Patterns Among Patients with Myelodysplastic Syndromes: Observations of 1st-Line Therapy, Discontinuation and the Need of Additional Therapies. <i>Blood</i> , 2014, 124, 2598-2598.	0.6	3
124	Healthcare Resource Utilization and Costs Among Patients with Myelodysplastic Syndrome Who Failed 1st-Line Therapy. <i>Blood</i> , 2014, 124, 2627-2627.	0.6	3
125	Personalized Therapy Design for MPN Using Predictive Simulation Methodology with in Vitro, Ex Vivo, and in Vivo Validatio. <i>Blood</i> , 2014, 124, 3212-3212.	0.6	4
126	A Novel Simulation Method for Mapping Dysregulated Pathways and Predicting Effective Therapeutics in the Myelodysplastic Syndromes. <i>Blood</i> , 2014, 124, 5595-5595.	0.6	1

#	ARTICLE	IF	CITATIONS
127	Cost Effectiveness of Treatments after Failure of a First-Line Hypomethylating Agent in Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2014, 124, 1928-1928.	0.6	0
128	Incidence of First-Line and Second-Line Myelodysplastic Syndrome in a US Commercial Claims Database. <i>Blood</i> , 2014, 124, 6008-6008.	0.6	0
129	A Novel Method of Using Molecular Profiling in Myelodysplastic Syndromes to Predict Patient-Specific Potential Therapeutics. <i>Blood</i> , 2014, 124, 5591-5591.	0.6	0
130	Chemosensitizing Leukemia By Targeting the Leukemia Microenvironment with Vascular Disrupting Combretastatins. <i>Blood</i> , 2014, 124, 2315-2315.	0.6	0
131	A Critical Analysis of Clinical Outcomes Reported in Stem Cell Trials for Acute Myocardial Infarction: Some Thoughts for Design of Future Trials. <i>Current Atherosclerosis Reports</i> , 2013, 15, 341.	2.0	8
132	PARP1 is required for chromosomal translocations. <i>Blood</i> , 2013, 121, 4359-4365.	0.6	67
133	Overcoming Chronic Myeloid Leukemia Stem Cell Resistance to Imatinib by Also Targeting JAK2. <i>Journal of the National Cancer Institute</i> , 2013, 105, 378-379.	3.0	5
134	A Phase I Study Of The Vascular Disrupting Combretastatin, OXi4503, In Patients With Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2013, 122, 1463-1463.	0.6	10
135	Hematologic Response To Oral Azacitidine (CC-486) In Subjects With WHO-Defined RAEB-1 Or RAEB-2 Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2013, 122, 1554-1554.	0.6	2
136	Bone Marrow Endothelial Cells Protect Acute Myeloid Leukemia From Chemotherapy By Direct Contact: The BCAM/Laminin/VLA5 Axis As a Potential Therapeutic Target. <i>Blood</i> , 2013, 122, 2546-2546.	0.6	4
137	Effect Of Cumulative Adverse Clinical Risk Factors On Patients With Multiple Myeloma Undergoing First GCSF Apheresis. <i>Blood</i> , 2013, 122, 4520-4520.	0.6	0
138	Clinical and Laboratory Factors Influencing The Probability Of Complete Remission In AML Patients With Positive Day 14 Bone Marrows. <i>Blood</i> , 2013, 122, 1412-1412.	0.6	0
139	Effect of Transendocardial Delivery of Autologous Bone Marrow Mononuclear Cells on Functional Capacity, Left Ventricular Function, and Perfusion in Chronic Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1717-26.	3.8	424
140	Underreporting of Myeloid Malignancies by United States Cancer Registries. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 474-481.	1.1	66
141	Effect of the Use and Timing of Bone Marrow Mononuclear Cell Delivery on Left Ventricular Function After Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2380-9.	3.8	357
142	Selective Purging of Human Multiple Myeloma Cells from Autologous Stem Cell Transplantation Grafts using Oncolytic Myxoma Virus. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1540-1551.	2.0	56
143	The Small Molecule Inhibitor G6 Significantly Reduces Bone Marrow Fibrosis and the Mutant Burden in a Mouse Model of Jak2-Mediated Myelofibrosis. <i>American Journal of Pathology</i> , 2012, 181, 858-865.	1.9	7
144	Virotherapy Using Myxoma Virus Prevents Lethal Graft-versus-Host Disease following Xeno-Transplantation with Primary Human Hematopoietic Stem Cells. <i>PLoS ONE</i> , 2012, 7, e43298.	1.1	14

#	ARTICLE	IF	CITATIONS
145	Oncolytic Virotherapy for Hematological Malignancies. <i>Advances in Virology</i> , 2012, 2012, 1-8.	0.5	31
146	Angiogenesis in Acute Myeloid Leukemia and Opportunities for Novel Therapies. <i>Journal of Oncology</i> , 2012, 2012, 1-9.	0.6	47
147	Factors affecting the turnaround time for manufacturing, testing, and release of cellular therapy products prepared at multiple sites in support of multicenter cardiovascular regenerative medicine protocols: a Cardiovascular Cell Therapy Research Network (CCTRN) study. <i>Transfusion</i> , 2012, 52, 2225-2233.	0.8	5
148	Characteristics of thawed autologous umbilical cord blood. <i>Transfusion</i> , 2012, 52, 2234-2242.	0.8	16
149	Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro. <i>Leukemia Research</i> , 2012, 36, 619-624.	0.4	20
150	Extended Dosing of Oral Azacitidine (CC-486) for 14 and 21 Days Provides More Effective Methylation Reversal Than a 7-Day Schedule. <i>Blood</i> , 2012, 120, 1337-1337.	0.6	6
151	Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes. <i>Blood</i> , 2012, 120, 424-424.	0.6	14
152	Response Post-First Autologous Stem Cell Transplantation for Multiple Myeloma May Identify Patients Who Will Benefit From Tandem Transplants: A Single Center Prospective Phase II Study- an Update. <i>Blood</i> , 2012, 120, 2023-2023.	0.6	0
153	Peripheral Blood CD34+ Specific Donor Chimerism Analysis As an Early Indicator of Disease Relapse After Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes and Acute Myelogenous Leukemia.. <i>Blood</i> , 2012, 120, 3074-3074.	0.6	0
154	Vascular Disrupting Combretastatins Impair Bone Marrow Endothelial Cells by Depolymerizing the Microtubule Cytoskeleton.. <i>Blood</i> , 2012, 120, 2183-2183.	0.6	0
155	A Phase I Study of the Vascular Disrupting Combretastatin, OXi4503, in Patients with Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2012, 120, 4335-4335.	0.6	0
156	The Jak2 Inhibitor, G6, Alleviates Jak2-V617F-Mediated Myeloproliferative Neoplasia by Providing Significant Therapeutic Efficacy to the Bone Marrow. <i>Neoplasia</i> , 2011, 13, 1058-1068.	2.3	11
157	Cancer Stem Cells: Historical Perspectives and Lessons from Leukemia. , 2011, , 3-11.		1
158	Developing mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory rationale. <i>American Heart Journal</i> , 2011, 162, 973-980.	1.2	17
159	Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. <i>Blood</i> , 2011, 117, 7121-7125.	0.6	191
160	Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes. <i>Leukemia Research</i> , 2011, 35, 1453-1456.	0.4	11
161	Effect of Intracoronary Delivery of Autologous Bone Marrow Mononuclear Cells 2 to 3 Weeks Following Acute Myocardial Infarction on Left Ventricular Function. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2110.	3.8	377
162	Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 2521-2527.	0.8	232

#	ARTICLE	IF	CITATIONS
163	The Stilbenoid Tyrosine Kinase Inhibitor, G6, Suppresses Jak2-V617F-mediated Human Pathological Cell Growth in Vitro and in Vivo. <i>Journal of Biological Chemistry</i> , 2011, 286, 4280-4291.	1.6	15
164	Oral Azacitidine (AZA) Activity in Patients with Acute Myelogenous Leukemia (AML). <i>Blood</i> , 2011, 118, 1546-1546.	0.6	3
165	AML Depends on VEGFR1 and Not VEGFR2 for Proliferation and Protection From Chemotherapy,. <i>Blood</i> , 2011, 118, 3598-3598.	0.6	0
166	Reinduction Chemotherapy for AML: Comparison Between CECA, High Dose Cytarabine and CLAG-M. <i>Blood</i> , 2011, 118, 4301-4301.	0.6	1
167	The Jak2 Kinase Inhibitor, G6, Reduces the Mutant Burden and Reverses Marrow Fibrosis in a Mouse Model of Jak2-V617F Mediated PMF,. <i>Blood</i> , 2011, 118, 3858-3858.	0.6	0
168	Acute Myeloid Leukemia Cells Generate Leukemic Endothelial Cells with Leukemogenic Potential: Blood Vessels As Sanctuaries for Leukemia Relapse. <i>Blood</i> , 2011, 118, 241-241.	0.6	0
169	Negative Correlation Between the Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) and Total Hospital Stay in Patients Who Underwent Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT). <i>Blood</i> , 2011, 118, 4462-4462.	0.6	0
170	CECA Results in Improved Response Rates and Ability to Proceed to Stem Cell Transplantation in Adult Refractory or Relapsed Acute Myeloid Leukemia. <i>Blood</i> , 2011, 118, 4299-4299.	0.6	0
171	Leukemia regression by vascular disruption and antiangiogenic therapy. <i>Blood</i> , 2010, 116, 1539-1547.	0.6	81
172	Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus. <i>Cytokine and Growth Factor Reviews</i> , 2010, 21, 169-175.	3.2	31
173	Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US) <i>Tj ETQq1 1 0.784314 rgB74 Overlook</i>	0.3	33
174	Multicenter cell processing for cardiovascular regenerative medicine applications: the Cardiovascular Cell Therapy Research Network (CCTRN) experience. <i>Cytotherapy</i> , 2010, 12, 684-691.	0.3	33
175	Acute Myeloid Leukemia Cells Depend on VEGF, PDGFR and SCF Receptor Signaling: Leukemia Regression with Pazopanib.. <i>Blood</i> , 2010, 116, 1057-1057.	0.6	3
176	Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study. <i>Blood</i> , 2010, 116, 603-603.	0.6	10
177	Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Scores Correlates with Increased Readmissions and Days In Hospital In Patients Undergoing Myeloablative Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2010, 116, 4748-4748.	0.6	0
178	High Rate of Uncaptured Myelodysplastic Syndrome Cases at the State Cancer Registry Level. <i>Blood</i> , 2010, 116, 1890-1890.	0.6	0
179	LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. <i>Texas Heart Institute Journal</i> , 2010, 37, 412-20.	0.1	50
180	Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes. <i>Clinical Advances in Hematology and Oncology</i> , 2010, 8, 40-6.	0.3	23

#	ARTICLE	IF	CITATIONS
181	Aldehyde dehydrogenase activity as a functional marker for lung cancer. <i>Chemico-Biological Interactions</i> , 2009, 178, 48-55.	1.7	155
182	Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells. <i>Leukemia</i> , 2009, 23, 2313-2317.	3.3	43
183	Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction. <i>American Heart Journal</i> , 2009, 158, 356-363.	1.2	74
184	Cancer, Stem Cells and the Neoplastic Niche. , 2009, , 63-78.		0
185	Bone marrow stem and progenitor cell contribution to neovasclogenesis is dependent on model system with SDF-1 as a permissive trigger. <i>Blood</i> , 2009, 114, 4310-4319.	0.6	60
186	A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML).. <i>Blood</i> , 2009, 114, 117-117.	0.6	5
187	Myxoma Virus Targets Primary Human Leukemic Stem and Progenitor Cells While Sparing Normal Hematopoietic Stem and Progenitor Cells.. <i>Blood</i> , 2009, 114, 14-14.	0.6	5
188	Cancer Microenvironment and Therapeutic Implications. , 2009, , .		2
189	A Comparative Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Azacitidine Following Subcutaneous (SC) and Oral Administration in Subjects with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML), Results From a Phase 1 Study.. <i>Blood</i> , 2009, 114, 1772-1772.	0.6	0
190	AML Regression by Vascular Disruption with OXi4503 and Anti-Angiogenesis with Bevacizumab.. <i>Blood</i> , 2009, 114, 1031-1031.	0.6	0
191	A Keyword Search Strategy to Identify Missed Cases of Myelodysplastic Syndromes in Population-Based Cancer Registries.. <i>Blood</i> , 2009, 114, 4852-4852.	0.6	0
192	Impact of An Annual Hematology/Oncology Fellow Wet Laboratory Program On Fund of Biomedical Knowledge.. <i>Blood</i> , 2009, 114, 246-246.	0.6	1
193	Marrow cell therapies for cardiovascular diseases. <i>Experimental Hematology</i> , 2008, 36, 687-694.	0.2	8
194	Optimization of a myeloid cell transfusion strategy for infected neutropenic hosts. <i>Journal of Leukocyte Biology</i> , 2007, 81, 632-641.	1.5	20
195	Bone Marrow Contributes to Epithelial Cancers in Mice and Humans as Developmental Mimicry. <i>Stem Cells</i> , 2007, 25, 1881-1887.	1.4	83
196	The hunt for cancer-initiating cells: a history stemming from leukemia. <i>Leukemia</i> , 2007, 21, 1619-1627.	3.3	37
197	The Hematopoietic Stem Cell Is a Source of Endothelial Cells in Cancer Vasculogenesis and Depends on SDF-1.. <i>Blood</i> , 2007, 110, 3722-3722.	0.6	9
198	The thrombopoietin receptor, c-Mpl, is a selective surface marker for human hematopoietic stem cells. <i>Journal of Translational Medicine</i> , 2006, 4, 9.	1.8	35

#	ARTICLE	IF	CITATIONS
199	Stem cell research. Paediatric Respiratory Reviews, 2006, 7, 135-140.	1.2	6
200	Blocking the SDF1/CXCR4 Axis Inhibits Marrow Derived Vasculogenesis in Cancer.. Blood, 2006, 108, 3942-3942.	0.6	0
201	Tumor Vasculogenesis Can Be Derived from the Hematopoietic Stem Cell.. Blood, 2006, 108, 1806-1806.	0.6	0
202	Marrow Contributes to Kidney Vasculogenesis in Humans.. Blood, 2006, 108, 3943-3943.	0.6	0
203	Human Myeloid Leukemia Xenotransplant Model Demonstrates Leukemia Blood Vessels from Both Human and Mouse Origin.. Blood, 2006, 108, 4269-4269.	0.6	0
204	Marrow Makes Thyroid but Not Adrenal Tissues in Humans.. Blood, 2006, 108, 1688-1688.	0.6	0
205	Donor-derived type II pneumocytes are rare in the lungs of allogeneic hematopoietic cell transplant recipients. Annals of Clinical and Laboratory Science, 2006, 36, 47-52.	0.2	15
206	Bone Marrow-Derived Stem-Cell Repopulation Contributes Minimally to the Type II Pneumocyte Pool in Transplanted Human Lungs. Transplantation, 2005, 80, 206-212.	0.5	37
207	Distinct hematopoietic progenitor compartments are delineated by the expression of aldehyde dehydrogenase and CD34. Blood, 2005, 106, 95-102.	0.6	118
208	Developmental Differences in Megakaryocyte Maturation Are Determined by the Microenvironment. Stem Cells, 2005, 23, 1400-1408.	1.4	41
209	The hemangioblast: Cradle to clinic. Experimental Hematology, 2004, 32, 885-890.	0.2	39
210	Bone marrow transdifferentiation in brain after transplantation: a retrospective study. Lancet, The, 2004, 363, 1432-1437.	6.3	298
211	Adult human hematopoietic cells provide functional hemangioblast activity. Blood, 2004, 103, 133-135.	0.6	74
212	Incorporation of Bone Marrow Derived Cells in Colonic Adenoma.. Blood, 2004, 104, 674-674.	0.6	0
213	Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma. American Journal of Hematology, 2003, 73, 169-175.	2.0	24
214	An Overview of Stem Cell Research and Regulatory Issues. Mayo Clinic Proceedings, 2003, 78, 993-1003.	1.4	31
215	An Overview of Stem Cell Research and Regulatory Issues. Mayo Clinic Proceedings, 2003, 78, 993-1003.	1.4	51